F-18 FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-kit-positive tumor patient by imatinib.
Zaknun
John J
JJ
Clinical Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria. j.zaknun@iaea.org
Kendler
Doris
D
Moncayo
Roy
R
zur Nedden
Dieter
D
Virgolini
Irene
I
D000970:Antineoplastic Agents / Q000008:administration & dosage; D001549:Benzamides; D019788:Fluorodeoxyglucose F18; D046152:Gastrointestinal Stromal Tumors / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000201:enzymology*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D049268:Positron-Emission Tomography / Q000379:methods*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage*; D019275:Radiopharmaceuticals; D015398:Signal Transduction / Q000187:drug effects*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases